Ribbon Biolabs, a Vienna, Austria-based DNA synthesis company, closed EUR 18m in its Series A funding.
The round was led by Hadean Ventures and with participation from Lansdowne Partners, Helicase Venture as well as several undisclosed investors. Existing investors IST cube and tecnet equity also joined in the round.
Founded in 2018 by Harold P. de Vladar, CEO, Ribbon Biolabs is a synthetic biology company advancing new technology for the automated synthesis of long DNA molecules to enable innovation in the life sciences.
The company intends to use the funds for the commercialization of its DNA synthesis technology, which integrates combinatorial optimization algorithms to guide the automated enzymatic assembly of DNA. This includes the setup of production facilities with key technology partners and the preparation for expansion into the US market. The investment will also support Ribbon Biolabs’ recruitment plans as it continues to grow its team including key operational and scientific positions located at the company’s facilities in Vienna and in the IST Park, the technology park of the prestigious Institute of Science and Technology – IST Austria.
FinSMEs
31/01/2022